ChemotherapyFDA-approvedFirst-line
Carboplatin
How it works
Damages the DNA of cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— All patients
Efficacy
Carboplatin has been shown to improve response rates and survival in patients with ovarian cancer, particularly when combined with paclitaxel.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Chemotherapy Options for Lung Cancer Patients | Lung Cancer | meta-analysis | — | Source → |
| Testing a New Treatment for Brain Metastases from Non-small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Ivonescimab with Chemotherapy in Early-Stage Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Comparing Chemotherapy Options for Lung Cancer Patients | Lung Cancer | observational | Five-year overall survival and recurrence-free survival numerically favored cisplatin (61.0% vs 48.8%, P=0.17; 63.9% vs 56.6%, P=0.12). | Source → |
| Testing a New Treatment Combination for Unresectable Pleural Mesothelioma | Lung Cancer | phase-3 | — | Source → |
| Comparing Carboplatin and Cisplatin in Lung Cancer Treatment | Lung Cancer | meta-analysis | — | Source → |
| Testing a Combination Therapy for Advanced Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Cancer Researchers Study Re-Challenging a Patient with Platinum-Based Chemotherapy | Lung Cancer | observational | — | Source → |
| Testing HIFU and PD-1 Inhibitors in Triple-Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing SKB500 Combinations in Small Cell Lung Cancer Patients | Lung Cancer | phase-2 | — | Source → |
| Ovarian Cancer Treatment Trial Evaluates IMNN-001 Combination Therapy | Ovarian Cancer | phase-1 | — | Source → |
| Carboplatin in Triple-Negative Breast Cancer Treatment | Breast Cancer | observational | The pCR rate was significantly higher in the platinum group than in the non-platinum group (68.9% vs. 50.5%). | Source → |
| Combination Therapy for Extensive-stage Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Immunotherapy with Chemotherapy for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a New Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing a Combination of Medications for HER2-Positive Early-Stage Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Evaluating a New Treatment for Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing New Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing a New Combination of Medications for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a New Combination of Chemotherapy Drugs for Advanced Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Testing Oregovomab with Chemo and Bevacizumab in Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Testing Sacituzumab Tirumotecan in Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing a Combination Treatment for Early-stage Triple-negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Researchers Investigate New Ovarian Cancer Treatment Options | Ovarian Cancer | lab-study | — | Source → |
| LINC00963 May Help Overcome Chemoresistance in Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Combining Medications Improves Lung Cancer Treatment for Some Patients | Lung Cancer | phase-3 | Combination therapy significantly prolonged median progression-free survival compared with monotherapy (19.78 vs 16.53 months; hazard ratio, 0.58; 95% confidence interval, 0.34-0.97). | Source → |
| Adding Carboplatin to Chemotherapy Improves Outcomes in Early-Stage Triple-Negative Breast Cancer | Breast Cancer | phase-3 | Adding carboplatin significantly improved disease-free survival (HR, 0.66; [95% CI, 0.44 to 0.97]; p = .034), distant disease-free survival (HR, 0.61 [95% CI, 0.38 to 0.98]; p = .040), and overall survival (HR, 0.39 [95% CI, 0.16 to 0.94]; p = .029). | Source → |
| Testing Neoadjuvant Carboplatin for High-Risk Prostate Cancer with BRCA Mutations | Prostate Cancer | phase-2 | — | Source → |
| Combining medications to treat advanced breast and ovarian cancer | Ovarian Cancer | phase-1 | There were 3 major responses (1CR, 2PR) at DL1, and 1 CR at DL-1. | Source → |
| Hereditary Breast-Ovarian Cancer Syndrome Responds to Chemotherapy | Ovarian Cancer | observational | The patient exhibited an outstanding response to the chemotherapy agents, Carboplatin and Paclitaxel. | Source → |
| Targeted Cancer Treatment Shows Promise in Lab Experiments | Breast Cancer | lab-study | — | Source → |
| New Study Compares Treatments for Rare Ovarian Tumors | Ovarian Cancer | phase-2 | Median progression-free survival was 27.7 months for paclitaxel and carboplatin, and 19.7 months for bleomycin, etoposide, and cisplatin. | Source → |
| New Lung Cancer Treatment Shows Promise in Early Study | Lung Cancer | phase-3 | The median overall survival was 10.7 months, and the median progression-free survival was 5.5 months. | Source → |
| Comparing Two Ways to Give Carboplatin for Triple-Negative Breast Cancer | Breast Cancer | observational | pCR rates were 50% with weekly and 61% with tri-weekly regimens. | Source → |
| New Cancer Treatment Uses Heat to Release Medicine | Ovarian Cancer | lab-study | — | Source → |
| Nafamostat Mesylate Sensitizes Ovarian Cancer Cells to Carboplatin | Ovarian Cancer | lab-study | — | Source → |
| BDNF's Role in Colon Cancer's Resistance to Carboplatin | Colorectal Cancer | lab-study | — | Source → |
| Carboplatin Resistance in Ovarian Cancer Linked to β-Tubulin Changes | Ovarian Cancer | lab-study | — | Source → |
| Carboplatin dosing in ovarian cancer treatment: A study on renal function estimation | Ovarian Cancer | phase-3 | — | Source → |
| New Options for Ovarian Cancer Treatment | Ovarian Cancer | meta-analysis | The risk of death was significantly decreased with carboplatin + pegylated liposomal doxorubicin + bevacizumab compared to platinum-based doublet CT (hazard ratio [HR] = 0.59, 95%CI 0.35, 1). | Source → |
| New Compound Enhances Chemotherapy Effectiveness in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Chemotherapy Agent Enhances Tumor-Fighting Cells | Ovarian Cancer | animal-study | — | Source → |
| Combining Avelumab and Carboplatin in Advanced Prostate Cancer | Prostate Cancer | preclinical | The objective response rate was 17.6%, including one complete response (5.9%). | Source → |
| Carboplatin Dose Calculations for Lung Cancer Patients Vary Depending on Dosing Equation | Lung Cancer | observational | — | Source → |
| Understanding how ovarian cancer becomes resistant to carboplatin | Ovarian Cancer | lab-study | — | Source → |
| Anaphylactic Reaction to Carboplatin Diagnosed by Skin Testing | Ovarian Cancer | observational | — | Source → |
| Combining birinapant and carboplatin may help target ovarian cancer cells | Ovarian Cancer | lab-study | — | Source → |
| Weekly vs. Tri-Weekly Paclitaxel for Ovarian Cancer Treatment | Ovarian Cancer | meta-analysis | There was likely a slight improvement in progression-free survival when paclitaxel was dosed weekly compared to tri-weekly (HR 0.89, 95% confidence interval (CI) 0.81 to 0.98). | Source → |
| Desensitization Therapy for Carboplatin Side Effects | Ovarian Cancer | observational | — | Source → |
| Adding carboplatin to breast cancer treatment may improve long-term outcomes | Breast Cancer | phase-3 | The hazard ratio for event-free survival was 0.63 (95% CI 0.43-0.92, P = 0.02) for carboplatin plus veliparib with paclitaxel versus paclitaxel. | Source → |
| Researchers Investigate Chemotherapy for Rare Lung Cancer | Leukemia | phase-2 | The overall response rate was 25.0% and disease control rate was 56.3%. | Source → |
| Combining Azacitidine and Carboplatin May Help Boost Immune Response in Ovarian Cancer | Ovarian Cancer | lab-study | Sequential azacitidine and carboplatin significantly slowed cell growth in 50% of cell lines compared to carboplatin alone. | Source → |
| Risk Factors for Carboplatin Allergic Reactions in Ovarian Cancer Patients | Ovarian Cancer | observational | — | Source → |
| Comparing Chemotherapy Treatments for Esophageal Cancer | Lung Cancer | phase-2 | The overall response rate in the taxane-based group was higher than the non-taxane-based group, but was not significantly different (p=0.851). | Source → |
| Ovarian Cancer Survival Rates in Northern India | Ovarian Cancer | observational | The median recurrence-free survival was 30 (95% confidence interval: 24.65-35.38) months. | Source → |
| Chemotherapy May Cause Ovarian Cancer Cells to Become Dormant | Ovarian Cancer | lab-study | — | Source → |
| New Chemotherapy Combination Shows Promise in Treating Triple-Negative Breast Cancer | Breast Cancer | phase-2 | 61.4% of patients in the DCb group achieved a pathologic complete response. | Source → |
| Ovarian Cancer Treatment Study Finds Key Prognostic Factors | Ovarian Cancer | preclinical | Median progression-free survival was 20.8 months, and median overall survival was 41.1 months. | Source → |
| Rare Pancreatic Cancer Responds to New Chemotherapy Combination | Pancreatic Cancer | phase-2 | — | Source → |
| Chemotherapy Affects Heart Function in Ovarian Cancer Patients | Ovarian Cancer | observational | — | Source → |
| Low-dose chemotherapy may enhance lung cancer treatment | Lung Cancer | lab-study | — | Source → |
| Lab Tests Show Different Results for Cancer Drug in 3D Models | Ovarian Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.